These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice. Sarafanov AG. Int J Mol Sci; 2023 May 11; 24(10):. PubMed ID: 37239930 [Abstract] [Full Text] [Related]
14. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R. Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672 [Abstract] [Full Text] [Related]
17. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo. Cao W, Trask AR, Bignotti AI, George LA, Doshi BS, Sabatino DE, Yada N, Zheng L, Camire RM, Zheng XL. J Thromb Haemost; 2023 Dec 23; 21(12):3477-3489. PubMed ID: 37726033 [Abstract] [Full Text] [Related]
18. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. Miners AH, Krishnan S, Pasi KJ. J Thromb Haemost; 2016 Nov 23; 14(11):2141-2147. PubMed ID: 27510890 [Abstract] [Full Text] [Related]
20. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci PM. Blood Rev; 2021 Nov 23; 50():100849. PubMed ID: 34024681 [Abstract] [Full Text] [Related] Page: [Next] [New Search]